RPRX Stock Royalty Pharma plc

$68.45
1d+1.08%5d-1.24%1m+10.14%ytd+77.15%
At close · Nov 20, 4:00 PM ET
After hours $68.00 -0.66% · Nov 20, 6:48 PM ET
52w low $37.3194% of range$70.37 52w high
Price

Today’s call · RPRX

All live ideas →

4 of 6 technical checks lean bullish

RPRX is in an uptrend, momentum soft. $70 is the level overhead; $62.31 the first support below.

No open idea.From $68.45 the reward-to-risk to $70 against $62.31 is 0.3 — below the 3:1 bar.
What would create one:
  • A close above $70 on rising volume (breakout).
  • A pullback to $62.31 that holds (entry near support).
Alert me at a level

The brief

Price vs 50-day · abovePrice vs 200-day · above50d vs 200d avg · aboveMACD · bearishRSI momentum · 635-day tape · -1.2%
signalRPRX’s 50-day average is above the 200-day — long-term trend alignment is bullish.
rangeTrading within 5% of its 52-week high.
levelPrice is 2.26% from resistance $70.0 — watch for a break or rejection.
volumeVolume is expanding vs its 20-day average.
All readings
TrendUptrend · above 50-day & 200-day
MomentumRSI 63.3 · MACD bearish
Trend strengthADX 35.6 · strong trend
Location+9.9% vs 50-day MA
52-week range-2% from high · +80% from low
VolatilityATR 1.64 · ~2.4%/day
RSI 14
63.3
MACD
1.82
ADX 14
35.6
ATR 14
1.64
SMA 50
$62.31
SMA 200
$55.26

Levels that matter

$70round+2.3%
$80round+16.9%
$62.31sma 50−9.0%
$60round−12.3%
$56.31swing zone · 3×−17.7%

Compare with…

Analyst overview · Nov 20

Royalty Pharma (RPRX) stock analysis, November 20, 2026: bullish outlook with high conviction

Royalty Pharma (RPRX) closed at $68.43 on November 20, 2026, still perched just below its recent high of $70.01 and comfortably above the 50‑day moving average of $62.30. The daily trend is in step with a weekly uptrend that keeps the price above its 40‑week average, and the stock is out‑performing the S&P 500 by more than 21% over the past 50 days. The balance of evidence points to a bullish stance for the next two to six weeks, with a high conviction rating despite a modest 5‑day pullback that lagged the broader market and the XLV health‑care ETF.

Why it matters

The most recent price action reflects a market that has already priced in the strong earnings beat on November 4, when RPRX reported a 10.1% month‑to‑date gain and a 28.97% rise over the past six months. The stock’s 5‑day return of –1.27% was modest compared with the S&P 500’s –8.7% decline and the XLV sector’s –6.29% slide, indicating that RPRX held its ground while the broader market fell. This relative resilience is a key part of the story: the stock’s out‑performance of the market (+5.0% versus sector) shows that investors are already rewarding its underlying growth narrative.

From a valuation perspective, analysts’ consensus remains a “buy” with a mean target of $73.5, a low of $66.0 and a high of $80.0. The current price sits about 6.9% below the mean target, suggesting that the upside potential is still largely unpriced. The spread between the low and high targets (a $14 range) also underscores the uncertainty but leans toward the higher end, consistent with the bullish bias.

The debate around RPRX centers on two points. Optimists point to the stock’s strong relative strength versus the S&P 500 (+21% over 50 days) and its leadership in the health‑care sector (+9.7% versus XLV over the same period). They also cite the price’s position above both the 50‑day ($62.30) and 200‑day ($55.26) moving averages, a classic sign of a sustained uptrend. Critics, however, highlight the recent dip from the $70.01 peak – a 2.3% fall – and the 20.3% volume shortfall versus the 20‑day average, arguing that the lack of buying pressure could foreshadow a stalled rally. The analyst consensus, however, still leans positive, and the price’s proximity to the round $70 resistance adds a clear technical catalyst.

Valuation against the analyst spread also supports the bullish case. With the mean target at $73.5, the upside from today’s $68.43 is roughly 7.5%, comfortably within the analyst’s target range and well above the stop level of $61.89 derived from the 50‑day SMA less a quarter of the 14‑day ATR.

What the evidence says

On the long‑term horizon the thesis remains intact. The price is still above its 40‑week average, the 50‑day SMA sits at $62.30, and the 14‑day RSI is at a healthy 63.2, indicating momentum without being overbought. The stock is in the “holds above” zone of $62.30, and the next swing zone at $56.31 would need to be breached before the weekly trend could be considered broken. In short, the long‑term structure is still supportive of an uptrend.

Looking ahead to the next two‑to‑six weeks, the balance of evidence leans positive with a high conviction rating. The assessment lists three of four conviction points: the daily trend aligns with the weekly uptrend, RPRX is leading the S&P 500 by 21% over 50 days, and it is also leading XLV by 9.7% over the same period. The breakout math calls for a daily close above the round $70 level on volume above the 20‑day average to confirm the upside move. The target of $80 offers a reward‑to‑risk of 1.2, though the math falls short of a 3‑to‑1 ratio; a price of roughly $84 would be needed to meet that threshold. The strongest case against the bullish reading is the 20.3% volume deficit and the recent 2.3% pullback from the peak, which could signal weakening buying interest. However, those factors do not outweigh the strong relative performance and the structural support at $62.30.

Levels that matter

The structure holds the price above the 50‑day SMA of $62.30; a break below that level would be the first sign of structural weakness. The next critical zone is the swing zone at $56.31; a weekly close beneath that level would signal the end of the current uptrend, as defined in the assessment. Above the current price, the nearest resistance is the round $70 level. A close above $70 on volume above the 20‑day average would satisfy the breakout condition and set the stage for the next target.

The breakout math projects a target of $80, a round level that yields a reward‑to‑risk of 1.2 based on the stop at $61.89. Because the reward‑to‑risk does not reach the 3‑to‑1 benchmark, the trade‑off is less compelling; a price move to about $84 would be required to achieve a 3‑to‑1 ratio. Until the $70 breakout is confirmed, the risk‑reward profile remains modest.

What would change the picture

A weekly close below the swing‑zone level of $56.31 would alter the outlook dramatically, as it would indicate that the weekly trend has ended. The non‑price catalyst that could shift the narrative is a surprise earnings miss or a significant regulatory setback in the biotech pipeline, which would undermine the growth assumptions baked into the current price.

What to watch

  • Next earnings release on November 4, 2026 – focus on the earnings‑per‑share surprise and any guidance shift.
  • Sector events: FDA approvals or setbacks affecting the broader health‑care ETF (XLV) could move RPRX before company‑specific news.
  • Valuation: the consensus mean target of $73.5 remains about 7% above the current price, keeping the upside potential in line with analyst expectations.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.